Want to see TSE:MDMA full AI Analyst Report?
MDMA Stock Chart & Stats
C$0.22
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.22
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.09 - C$0.33
Previous CloseN/A
Volume85.07K
Average Volume (3M)311.22K
Market Cap
C$28.95M
Enterprise ValueC$18.29
Total Cash (Recent Filing)C$245.06K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta0.06
Next Earnings
Dec 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding109,236,030
10 Day Avg. Volume335,833
30 Day Avg. Volume311,222
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)5.47
Price to Sales (P/S)22.20
P/FCF Ratio-12.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthTTM revenue growth indicates improving commercial traction and customer demand. If sustained, a larger revenue base can support operating leverage and provide a foundation for scaling the regulated supply business, although profitability must still follow.
Debt-Free Balance SheetThe absence of reported debt reduces interest burden and financial risk, preserving flexibility while the company develops its business. Positive equity and assets provide additional support, allowing more resources to remain focused on operations and growth.
Regulated Pharmaceutical Supply ModelThe company operates in a specialized, regulated niche where pharmaceutical-grade production, quality assurance, testing, and compliance are central to customer access. These requirements can create meaningful capability barriers for suppliers serving clinical and research programs.
Bears Say
Persistent UnprofitabilityNegative gross profit and large operating losses show that current revenue does not yet cover the cost structure. Continued unprofitability could delay self-sustaining growth, constrain reinvestment, and make future performance highly dependent on substantial improvement in margins.
Negative Cash GenerationOngoing operating and free-cash-flow deficits indicate that the business is consuming cash to fund operations rather than generating internal funding. Unless revenue scales materially or costs decline, this burn can require continued financing and limit strategic flexibility.
Negative Returns And Dilution RiskA deeply negative return on equity signals that the company is not currently converting its capital base into profits. If losses persist, equity may continue to erode or additional capital may be needed, increasing the risk of dilution over time.
PharmAla Biotech Holdings, Inc. News
MDMA FAQ
What was PharmAla Biotech Holdings, Inc.’s price range in the past 12 months?
PharmAla Biotech Holdings, Inc. lowest stock price was C$0.09 and its highest was C$0.33 in the past 12 months.
What is PharmAla Biotech Holdings, Inc.’s market cap?
PharmAla Biotech Holdings, Inc.’s market cap is C$28.95M.
When is PharmAla Biotech Holdings, Inc.’s upcoming earnings report date?
PharmAla Biotech Holdings, Inc.’s upcoming earnings report date is Dec 18, 2026 which is in 89 days.
How were PharmAla Biotech Holdings, Inc.’s earnings last quarter?
PharmAla Biotech Holdings, Inc. released its earnings results on Jul 29, 2026. The company reported -C$0.005 earnings per share for the quarter.
Is PharmAla Biotech Holdings, Inc. overvalued?
According to Wall Street analysts PharmAla Biotech Holdings, Inc.’s price is currently Overvalued.
Does PharmAla Biotech Holdings, Inc. pay dividends?
PharmAla Biotech Holdings, Inc. does not currently pay dividends.
What is PharmAla Biotech Holdings, Inc.’s EPS estimate?
PharmAla Biotech Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmAla Biotech Holdings, Inc. have?
PharmAla Biotech Holdings, Inc. has 109,236,030 shares outstanding.
What happened to PharmAla Biotech Holdings, Inc.’s price movement after its last earnings report?
PharmAla Biotech Holdings, Inc. reported an EPS of -C$0.005 in its last earnings report. Following the earnings report the stock price went up 6.667%.
Which hedge fund is a major shareholder of PharmAla Biotech Holdings, Inc.?
Currently, no hedge funds are holding shares in TSE:MDMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmAla Biotech Holdings, Inc.
Pharmala Biotech Holdings Inc., operating as PharmAla, concentrates its efforts on the research, manufacturing, and bringing to market of active pharmaceutical ingredients (APIs) within the substituted methylenedioxy-phenethylamine (MDXX) class. The company's offerings further extend to various MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB) and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), in addition to prepared formulations of these MDXX substances. The enterprise maintains its primary corporate offices in Vancouver, Canada.